Christina Applegate joins TG Therapeutics to launch MS support platform NextInMS
Christina Applegate joins TG Therapeutics to launch MS support platform NextInMS
Christina Applegate joins TG Therapeutics to launch MS support platform NextInMS
TG Therapeutics has teamed up with actress Christina Applegate to launch a new initiative supporting people with multiple sclerosis (MS). The campaign centres on NextInMS.com, a platform designed to encourage open discussions about living with the condition. Applegate, who has lived with MS for five years, will share her experiences and connect with others affected by the disease.
The collaboration aims to create a space for honest conversations about MS and provide resources for patients. Applegate will engage with individuals living with the condition, caregivers, and healthcare professionals through the platform. Educational content from leading MS experts will also be featured.
MS affects around 250,000 people in Germany, with regional variations in treatment. The Marianne Strauss Clinic in Kempfenhausen is the largest specialist MS centre in southern Germany and the second-largest nationwide. Meanwhile, Universitätsklinikum Jena in Thuringia recorded the highest number of MS procedures last year, with 426 cases.
TG Therapeutics, a biopharmaceutical company focused on B-cell diseases, has an FDA-approved treatment for relapsing forms of MS. The company continues to develop new therapies while supporting patient resources like NextInMS.com.
The initiative will offer personal stories, expert advice, and community support for those navigating MS. Applegate's involvement brings visibility to the challenges faced by patients. The platform is now live, providing tools to help individuals manage their care journey.
Geesthacht Hospital shifts to specialist clinic after financial crisis and staff shortages
A once-full-service hospital now fights for survival. How Geesthacht's bold downsizing could redefine local healthcare—or leave patients scrambling.
National health hotline cuts wait times with 24/7 support and AI upgrades
Struggling with long-term illness? This free hotline now answers faster—thanks to AI and smarter systems. See how it's changing patient care.
Novartis bets $3B on unproven breast cancer therapy SNV4818
A $3B gamble on an untested drug could redefine breast cancer care—or backfire. Why Novartis is banking on SNV4818's untapped potential before clinical trials even begin.
How prior authorization delays can harm patients and frustrate doctors
A system meant to cut costs is putting patients at risk. Doctors warn that insurance red tape is delaying care—and even forcing dangerous medication switches.